AI Labs
Xaira Therapeutics
An AI drug discovery company that launched in 2024 with roughly $1 billion in funding and released its first AI model in March 2026, X-Cell, a virtual cell model trained on the largest-ever genome-wide perturbation dataset. Xaira is shifting from a secretive to a partnership-oriented strategy in 2026, seeking pharma collaborators to validate an emerging pipeline focused on difficult targets and large-molecule therapeutics, particularly in immunology.
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
2 sources · 56% avg. source confidence
- BioSpace — Xaira Therapeutics launches X-Cell virtual cell model trained on largest-ever perturbation dataset58% source confidence
- Xaira Therapeutics newsroom — Xaira expands leadership team as it moves toward translational science and clinical development54% source confidence
Dependency Map
What Xaira Therapeutics depends on below, and who depends on Xaira Therapeutics above — click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Xaira Therapeutics's Timeline
A sourced, dated history of Xaira Therapeutics's key moments — founding to present.
Jan 2024 · Launched with ~$1B in funding
Xaira Therapeutics launched with roughly $1 billion in funding to pursue AI-driven drug discovery focused on difficult targets and large-molecule therapeutics.
Mar 2026 · Releases X-Cell virtual cell model
Xaira released its first AI model, X-Cell, a virtual cell model trained on the largest-ever genome-wide perturbation dataset.